Our result showing the marked decrease of SKP2 protein after PI3K p110β-siRNA treatment confirmed that SKP2 is a downstream target of PI3K p110β isoform in ovarian cancer cells. This evidence concerns the gene PIK3CA and ovarian carcinoma.